Twitter Facebook LinkedIn YouTube

THC BioMed (CSE: THC) signed Letter of Intent to Acquire Clone Shipper for US$1 Million

Video Platform Video Management Video Solutions Video Player

THC BioMed has signed a Letter of Intent to acquire Clone Shipper for US$1 million. US-based Clone Shipper specializes in packaging products used to transport live plants and is currently the only device that meets Canadian and Federal International laws governing the transportation of controlled live plants.

Additional Information:

Company: THC BioMed
Website: http://www.thcbiomed.com
Stock Symbol: CSE: THC
Date Published: Sep 27, 2016
Transcript: Available

Video Transcript:

I’m Samantha Deutscher for Investmentpitch Media

THC BioMed has signed a Letter of Intent to acquire Clone Shipper for US$1 million.
US-based Clone Shipper specializes in packaging products used to transport live plants and is currently the only device that meets Canadian and Federal International laws governing the transportation of controlled live plants.

The patented design allows for an LED light to keep the clone in the growing vegetative stage for 12 to 24 hours while being shipped.

The company also sells Clonex clone solution, a specifically formulated plant food for rooting clones and seedlings using a profile of the highest quality minerals including nitrogen, phosphorus and calcium along with vitamin B1 which reduces the risk of transplant shock.

Clone Shipper products are currently available for sale at gardening supply outlets throughout the USA, and on popular sites such as Amazon.com as well as www.cloneshipper.com.

John Miller, President and CEO, stated: “I am pleased to have the opportunity to make this strategic purchase. Purchasing Clone Shipper allows THC to penetrate the US and the International Cannabis market, while remaining in line with the US and International laws, by not dealing directly with cannabis in countries where cannabis remains Federally illegal. The Global demand for Securely shipping Live plants is increasing with the legalization of Medical Cannabis. This is the early formation of our Global footprint we intend to place in the International Cannabis Market Place.”

THC BioMed plans to strengthen the patents protecting the clone shipper device and to ensure protection under international laws.

Health Canada previously granted THC authorization, through a wholly-owned subsidiary, to produce fresh marijuana, cannabis oil, and cannabis resin.

The company is developing a wide range of products including medical grade dried cannabis, CBD, THC oils and cannabis infused products for topical application.

The company also carries a diverse selection of seeds, imported from Holland, including high CBD and high THC producing strains.

THC management believes that as the medical cannabis industry develops it will become more important to focus on scientific research and development of new products and services, areas that THC is well positioned to lead.

The shares are trading at $0.66 and with 100 million shares currently outstanding, the company is capitalized at $66 million.

For more information, please visit www.THCbiomed.com or www.supraTHC.com or contact John Miller, President & CEO, at 604-682-1643 or email info@THCbiomed.com.

I’m Samantha Deutscher for Investmentpitch Media